Juan Pinelli, PA-C, MMSc.
Seagen Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Juan Pinelli, PA-C, MMSc. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:00 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02855359 · Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular LymphomaSeagen Inc. · terminated · Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL · study director
- Ph1NCT02702141 · A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin LymphomaSeagen Inc. · terminated · Non-Hodgkin Lymphoma, DLBCL, Diffuse Large B-cell Lymphoma
- Ph2NCT02592876 · Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell LymphomaSeagen Inc. · terminated · Lymphoma, B-cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Grade 3b
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.